On December 2, the Science and Technology Innovation Board Daily (Reporter Li Mingming) reported new developments about former Alibaba CEO Wei Zhe.

Sansure Biotech Inc. recently announced that Wei Zhe is expected to be appointed as a director, nominated by the company's chairman and general manager, Dai Lizhong.

In response to the above news, Wei Zhe confirmed to the Science and Technology Innovation Board Daily reporter that it is true, and stated that the reason for taking the position of director at Sansure Biotech Inc. is that he wants to deeply empower the medical industry and gain a thorough understanding of it.

So, will he, with rich experience in capital markets, act as a trader to assist Sansure in its mergers and acquisitions business? Wei Zhe clearly responded to the Science and Technology Innovation Board Daily reporter, saying: "No."

The reporter from the Science and Technology Innovation Board Daily noticed that at the end of last year, Wei Zhe and his founded Jiayu Capital began to enter the healthcare sector and focused on investing in early-stage projects in the medical health industry through the Jiayu Ziniu Medical Fund.

Sansure Biotech Inc. responded to the Science and Technology Innovation Board Daily reporter this morning, stating that the company invited Wei Zhe to join mainly considering his work history, management experience, professional ability, and the synergy effect he could bring to the company. As for whether Wei Zhe will handle the company’s mergers and acquisitions business, it will be carried out within the scope of his responsibilities as a director.

Regarding the specific time of Wei Zhe officially taking office as a company director, Sansure Biotech Inc. stated that it has just disclosed the announcement of Wei Zhe as a nominated director candidate, and he will officially take office after being approved at the next shareholder meeting.

Wei Zhe appointed as a director of sansure biotech inc.

A reporter from the Star Daily discovered that on November 30, Wei Zhe publicly stated in his WeChat Moments that he has a highly aligned development philosophy with sansure biotech inc. and the company's chairman and general manager Dai Lizhong, focusing on penetrating the medical system and planning to go overseas. Serious medicine is moving towards consumer applications, and he looks forward to contributing to making sansure biotech inc. a world-class medical giant.

Regarding the specific plans and intentions for the next steps after taking up the position of director, Wei Zhe told a reporter from the Star Daily, "Let's talk about it after officially assuming the position."

According to public information, Wei Zhe was born in December 1970, is a resident of Hong Kong, and is currently the founding partner and chairman of Jia Yu Capital (also known as Suzhou Weitili New Venture Investment Management Co., Ltd.), possessing profound investment management experience and rich industry resource links in fields such as artificial intelligence, new consumer, and cutting-edge technology, with deep layouts in multiple industrial ecological ends.

His resume shows that Wei Zhe previously served as the general manager of the investment banking department at orient, manager of the financing department at PwC, and held positions as the chief financial officer and chief executive officer of B&Q (China), as well as the chief executive officer of alibaba. He also serves as a non-executive director of pccw and as vice president of the China Chain Store and Franchise Association.

Wei Zhe joined alibaba in 2006 and after leaving alibaba in 2011, founded Jia Yu Capital.

According to their official website, Jia Yu Capital manages a total asset amount exceeding 17 billion RMB in US dollar and RMB funds, making it an investment fund that focuses on new consumer, cross-border e-commerce, overseas brands, technology-driven enterprise services, and cutting-edge technology fields. To date, it has helped more than thirty invested companies grow into unicorns and even super unicorns.

A reporter from the Star Daily noted that among the projects invested by Jia Yu Capital, few involve healthcare. They have invested in several well-known projects in the semiconductor field, including zhejiang Jingneng, Yunji Integrated Circuit, Shaoguang Semiconductor Materials, and Xing Si Semiconductors.

Is Jiayu Capital's next investment direction also inclined towards the medical field? Wei Zhao told the reporter from the Star Daily that Jiayu Capital had previously delved into the medical and health industry through the Jiayu Ziniu Medical Fund to assist Chinese medical enterprises in going global.

By the end of 2023, Jiayu Capital and the Ziniu Fund announced the establishment of the Jiayu Ziniu Medical Fund. It is reported that the fund focuses on early projects in the medical health industry, with a focus on investments in medical instruments and advanced biotechnology.

At that time, Wei Zhao stated: "After twelve years since its establishment, Jiayu Capital has ventured into medical investment for the first time, stemming from our long-term focus on and bullish outlook on the medical industry's anti-cyclical nature and development resilience. Jiayu Capital will work with the Ziniu Fund to assist in the verification and application of interdisciplinary intersections in medical and technology fields, serious medical consumer applications, cross-border expansion of medical products, organization empowerment and strategy formulation, helping medical-grade products expand into consumer-grade products or other technology fields, and enabling medical enterprises to build their brands internationally, supporting Chinese medical enterprises in reaching the global market."

According to reports, Jiayu Capital believes that investing in projects related to semiconductors can also aid the medical health sector. "Whether in chips or AI, their application in the medical field is becoming increasingly widespread. Jiayu Capital will use its unique technological perspective to provide technical support to medical teams and projects."

Sansure biotech inc. is creating a second growth point.

Founded in 2008, Sansure biotech inc. is an in vitro diagnostic overall solution provider that integrates diagnostic reagents, instruments, and independent clinical laboratory services. Its main business includes the research and development, production, and sales of in vitro diagnostic reagents and supporting testing instruments, as well as independent clinical laboratory services, and it was listed on the star on August 28, 2020.

Today (December 2), the opening price of Sansure biotech inc. is 23.67 yuan per share, with a total market value of 13.878 billion yuan.

From January to September this year, the company achieved revenue of 1.033 billion yuan, a year-on-year increase of 63.24%; the net income attributable to shareholders of the listed company was 0.195 billion yuan, down 34.80% year-on-year.

Regarding the growth in revenue, sansure biotech inc. stated that it is mainly due to the rapid emergence of advantages in technology and market in the field of in vitro diagnostics, with significant developments in multiple key areas such as respiratory, maternal and child health, blood source, and sequencing, gradually entering a phase of substantial growth.

Regarding the decline in net income, the company indicated that it is mainly due to a decrease in non-recurring gains and losses during the reporting period.

In vitro diagnosis, or IVD (In Vitro Diagnosis), refers to the products and services that obtain clinical diagnostic information by testing human samples (blood, body fluids, tissues, etc.) outside the human body, thereby determining diseases or body functions.

In vitro diagnostics can be divided into biochemical diagnostics, immunodiagnostics, molecular diagnostics, microbiological diagnostics, blood diagnostics, and POCT (point-of-care testing), among others.

Dai Lizhong previously stated that under the vision of sansure, there is a hope to build a new ecosystem that promotes the universal application and all-scenario utilization of molecular diagnostics, entering an era where molecular diagnostics are accessible to everyone, which would represent a market worth hundreds of billions or even trillions.

During the pandemic, sansure biotech inc. achieved considerable profits through the sales of COVID-19 nucleic acid testing reagents and instruments. In 2022, sansure biotech inc. announced a 'second venture' to find a second growth point besides COVID-19 nucleic acid testing. Furthermore, the official website shows that sansure biotech inc., as a leading domestic molecular diagnostics company, is accelerating its transformation into a global leader in life technology.

At the same time, sansure biotech inc. has also introduced former executives of international giants and established an industrial fund, taking a series of measures to enhance innovation capabilities and broaden industrial layout, aiming to achieve a 'second venture' and maintain rapid growth momentum.

In 2023, sansure biotech inc. jointly initiated the establishment of the sansure biotech industrial fund with Shengweirongquan, with an initial fundraising size of 0.4 billion yuan, which will invest in in vitro diagnostics, biomedical, biotechnology, and health sectors.

In addition, sansure biotech inc. is also attempting to reduce its dependence on the nucleic acid testing reagent business by investing in upstream and downstream enterprises, addressing business shortfalls. Currently, its invested projects include non-invasive genetic testing company Kun Yuan Biotech, in vitro diagnostic equipment and consumables manufacturer Zhen Mai Biotech, among others.